Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility
Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Singapore's efforts to grow its biologics manufacturing sector received a significant boost when the Singapore Economic Development Board (EDB) announced that Genentech, Inc. has decided to establish a commercial scale microbial-based biologics manufacturing facility in Singapore - a first for Singapore's fast growing biopharmaceuticals sector. This is the first manufacturing investment by a U.S. biotechnology company in Singapore.
The estimated capital expenditure of the plant is approximately US$140 million. It will have approximately 100 employees at steady state and provide 1,000 litres of capacity for the production of E. coli derived products. This facility, which will be located in Tuas Biomedical Park, is intended for the manufacture of bulk LUCENTIS® (ranibizumab injection), a treatment for wet age-related macular degeneration. Construction is expected to begin in the second quarter of 2007 with licensure anticipated in early 2010.
The planned Genentech plant is Singapore's fourth biologics manufacturing facility. Other biologics plants presently under construction in Singapore include GlaxoSmithKline Biologicals' vaccines facility, as well as Switzerland-based biologics contract manufacturer Lonza's two facilities, including its joint venture with Bio*One Capital. In addition to its latest investment, Genentech had previously entered into a supply agreement with Lonza for the manufacture of certain Genentech products at the Lonza facility currently under construction in Singapore. The agreement includes an exclusive option for Genentech to purchase the facility during the period from 2007 to 2012.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
